| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 290 | 8,040 | 6,530 | 61,800 | 85,760 |
| Sales Growth | -96.39% | +23.12% | -89.43% | -27.94% | +33.25% |
| Net Income | -430 | -8,270 | 23,920 | -71,670 | -97,740 |
| Net Income Growth | +94.80% | -134.57% | +133.38% | +26.67% | -28.32% |
Redhill Biophrma ADR (RDHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
RedHill Biopharma Ltd. is a specialty biopharmaceutical company, focused on gastrointestinal and infectious diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment is based in Raleigh, NC, and covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
Fiscal Year End Date: 12/31